Premium
Study: Psilocybin enhances therapy in patients with major depression
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30675
Subject(s) - psilocybin , depression (economics) , medicine , psychiatry , antidepressant , major depressive disorder , hallucinogen , randomized controlled trial , psychotherapist , psychology , anxiety , cognition , economics , macroeconomics
Patients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen saw a rapid and lasting improvement in depression symptoms, a randomized open‐label trial has found. These findings extend results of research that have suggested antidepressant effects for psilocybin in patients with cancer and treatment‐resistant depression, the researchers stated. Study results were published online Nov. 4, 2020, in JAMA Psychiatry .